Drug

CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that three drug candidates—SYH2072 (aldosterone synthase inhibitor), Priglitin/Dapagliflozin/Metformin...

Company Drug

Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China

Fineline Cube Dec 30, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its drug candidate HRS-6257...

Company Drug

Recbio’s REC610 Shingles Vaccine NDA Accepted by NMPA, Challenging GSK’s Shingrix

Fineline Cube Dec 30, 2025

Jiangsu Recbio Technology Co., Ltd. (HKG: 2179) announced that the New Drug Application (NDA) for...

Company Drug

J&J’s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial

Fineline Cube Dec 30, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced that its Phase 2b DUPLEX‑AD proof‑of‑concept study evaluating JNJ‑95475939...

Company Drug

HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma

Fineline Cube Dec 30, 2025

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma

Fineline Cube Dec 30, 2025

Easton Pharmaceutical Co., Ltd. (SHA: 688513) announced that the first subject has been dosed in...

Company Drug

Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial

Fineline Cube Dec 30, 2025

Sino Biopharmaceutical Limited (HKG: 1177) announced that TDI01, the world’s first highly selective ROCK2 inhibitor...

Company Drug

TJ Biopharma and Jumpcan Secure BE Trial Approval for Localized Eftansomatropin in China

Fineline Cube Dec 30, 2025

TJ Biopharma (Hangzhou) Co., Ltd. and Jumpcan Holdings Group announced that the Center for Drug...

Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Fineline Cube Dec 29, 2025

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that the first commercial batch of its...

Company Drug

BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL

Fineline Cube Dec 29, 2025

Shanghai BDgene Technology Co., Ltd. announced that BD920, its in vivo CRISPR gene editing therapy,...

Company Drug

Sino Biopharmaceutical’s TQH3906 Achieves 90% PASI 75 Response in Phase 2 Psoriasis Trial

Fineline Cube Dec 29, 2025

Sino Biopharmaceutical Limited (HKG: 1177) announced that TQH3906, a Category 1 innovative oral TYK2/JAK1 inhibitor, has...

Company Drug

AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy

Fineline Cube Dec 29, 2025

AstraZeneca PLC (AZ, NASDAQ: AZN) and Ionis Pharmaceuticals (NASDAQ: IONS) announced that Wainua (eplontersen) has received approval...

Company Drug

AstraZeneca Secures NMPA Approval for Fasenra in EGPA, Demonstrating Superior Steroid-Sparing Effect

Fineline Cube Dec 29, 2025

AstraZeneca PLC (AZ, NASDAQ: AZN) announced that Fasenra (benralizumab) has received additional approval from China’s...

Company Drug

Innovent Biologics Secures NMPA Approval for TABOSUN as First Neoadjuvant Dual‑IO Therapy for MSI‑H/dMMR Colon Cancer

Fineline Cube Dec 29, 2025

Innovent Biologics, Inc. (HKG: 1801) announced that China’s National Medical Products Administration (NMPA) has approved...

Company Drug

Allist Pharmaceuticals Secures Breakthrough Therapy Designation for Furmonertinib in EGFR PACC‑Mutated NSCLC

Fineline Cube Dec 29, 2025

Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that furmonertinib has been added to the Breakthrough...

Company Drug

Livzon’s Lecankitug Accepted by NMPA as First Domestic Dual IL‑17A/F Psoriasis Drug

Fineline Cube Dec 29, 2025

Livzon Pharmaceutical Group Inc. (HKG: 1513) announced that China’s National Medical Products Administration (NMPA) accepted...

Company Drug

Novo Nordisk’s Sogroya Wins NMPA Approval for Pediatric Growth Hormone Deficiency

Fineline Cube Dec 29, 2025

Novo Nordisk (NYSE: NVO) announced that its once‑weekly long‑acting growth hormone (LAGH) injection, Sogroya (somapacitan), received...

Company Drug

J&J’s Amivantamab Subcutaneous Wins China Approval for NSCLC

Fineline Cube Dec 29, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced that its Amivantamab Injection (Subcutaneous), marketed as RYBREVANT, received...

Company Drug

Novo Nordisk’s Wegovy Wins China Cardiovascular Approval in Weight-Loss Market Expansion

Fineline Cube Dec 23, 2025

Novo Nordisk (NYSE: NVO) announced that China’s National Medical Products Administration (NMPA) approved Wegovy (semaglutide)...

Company Drug

Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections

Fineline Cube Dec 23, 2025

Beijing Aosaikang Pharmaceutical Co., Ltd. (SHE: 002755) announced that China’s National Medical Products Administration (NMPA)...

Drug

CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug

Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China

Recbio’s REC610 Shingles Vaccine NDA Accepted by NMPA, Challenging GSK’s Shingrix

J&J’s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial

HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma

Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial

TJ Biopharma and Jumpcan Secure BE Trial Approval for Localized Eftansomatropin in China

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL

Sino Biopharmaceutical’s TQH3906 Achieves 90% PASI 75 Response in Phase 2 Psoriasis Trial

AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy

AstraZeneca Secures NMPA Approval for Fasenra in EGPA, Demonstrating Superior Steroid-Sparing Effect

Innovent Biologics Secures NMPA Approval for TABOSUN as First Neoadjuvant Dual‑IO Therapy for MSI‑H/dMMR Colon Cancer

Allist Pharmaceuticals Secures Breakthrough Therapy Designation for Furmonertinib in EGFR PACC‑Mutated NSCLC

Livzon’s Lecankitug Accepted by NMPA as First Domestic Dual IL‑17A/F Psoriasis Drug

Novo Nordisk’s Sogroya Wins NMPA Approval for Pediatric Growth Hormone Deficiency

J&J’s Amivantamab Subcutaneous Wins China Approval for NSCLC

Novo Nordisk’s Wegovy Wins China Cardiovascular Approval in Weight-Loss Market Expansion

Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections

You Missed

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug

Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China

Recbio’s REC610 Shingles Vaccine NDA Accepted by NMPA, Challenging GSK’s Shingrix